Screener
Vor Biopharma VOR Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Vor Biopharma in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Vor Biopharma’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220689
| (in thousands) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Prepaid expenses and other current assets | (6,359) | (231) |
| Accounts payable, accrued liabilities and other current liabilities | (9,100) | (1,373) |
| Other assets | (20) | 14 |
| Net cash used in operating activities | (38,246) | (31,066) |
| Cash flows from investing activities | ||
| Purchases of marketable securities | (276,500) | — |
| Proceeds from maturities of marketable securities | 13,311 | 1 |
| Purchases of property and equipment | (48) | (231) |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Vor Biopharma's operating cash flow?
- Vor Biopharma (VOR) reported operating cash flow of -$38.25M in Q1 2026.
- How has Vor Biopharma's operating cash flow changed year-over-year?
- Vor Biopharma's operating cash flow decreased by 23.1% year-over-year, from -$31.07M to -$38.25M.
- What is the long-term trend for Vor Biopharma's operating cash flow?
- Over 4 years (2021 to 2025), Vor Biopharma's operating cash flow has grown at a 19.9% compound annual growth rate (CAGR), from -$69.14M to -$142.71M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Vor Biopharma's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude